Show simple item record

dc.contributor.authorRebello, R
dc.contributor.authorOing, C
dc.contributor.authorGillessen, Silke
dc.contributor.authorBristow, Robert G
dc.date.accessioned2019-02-08T15:20:05Z
dc.date.available2019-02-08T15:20:05Z
dc.date.issued2018en
dc.identifier.citationRebello RJ, Oing C, Gillessen S, Bristow RG. TP53 and prognosis in mCRPC survival: biology or coincidence. Clin Cancer Res. 2019.en
dc.identifier.pmid30610102en
dc.identifier.doi10.1158/1078-0432.CCR-18-3401en
dc.identifier.urihttp://hdl.handle.net/10541/621501
dc.description.abstractCell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.CCR-18-3401en
dc.titleTP53 and prognosis in mCRPC survival: biology or coincidence?en
dc.typeArticleen
dc.contributor.departmentUniversity of Manchester Manchester Cancer Research Centreen
dc.identifier.journalClincal Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record